Targeting γδT cells for immunotherapy of HIV disease

Future Virology

Volumn 6, Issue 1, 2011, Pages 73-84

  Pauza, C David ^a   Riedel, David J ^a   Gilliam, Bruce L ^a   Redfield, Robert R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

T cell; AIDS; bisphosphonates; cancer; HIV; IL 2; immunotherapyn phosphoantigen

Indexed keywords

ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; INTERLEUKIN 2; PAMIDRONIC ACID; T LYMPHOCYTE RECEPTOR; ZOLEDRONIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL POPULATION; DIARRHEA; DISEASE COURSE; DRUG FEVER; DRUG TARGETING; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INJECTION SITE SWELLING; NAUSEA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; VIRUS IMMUNITY;

EID: 78650664702     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.78     Document Type: Review

References (86)

1. Viret C, Janeway CA Jr: MHC and T cell development. Rev. Immunogenet 1(1), 91-104 (1999).
2. Casrouge A, Beaudoing E, Dalle S, Pannetier C, Kanellopoulos J, Kourilsky P: Size estimate of the ab TCR repertoire of naive mouse splenocytes. J. Immunol. 164(11), 5782-5787 (2000).
3. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P: A direct estimate of the human ab T cell receptor diversity. Science 286(5441), 958-961 (1999).
4. Bolland MJ, Grey AB, Horne AM et al.: Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodefciency virus-infected men: a randomized controlled trial. J. Clin. Endocrinol. Metab. 92(4), 1283-1288 (2007).
5. Wedderburn LR, Patel A, Varsani H, Woo P: The developing human immune system: T-cell receptor repertoire of children and young adults shows a wide discrepancy in the frequency of persistent oligoclonal T-cell expansions. Immunolog y 102(3), 301-309 (2001).
6. + T cell repertoire focusing and selection of high-affnity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. J. Immunol. 179(5), 3203-3213 (2007).
7. Sallusto F, Mackay CR, Lanzavecchia A: The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18, 593-620 (2000).
8. Groh V, Steinle A, Bauer S, Spies T: Recognition of stress-induced MHC molecules by intestinal epithelial gd T cells. Science 279(5357), 1737-1740 (1998).
9. Kapp JA, Kapp LM, McKenna KC, Lake JP: gd T-cell clones from intestinal intraepithelial lymphocytes inhibit development of CTL responses ex vivo. Immunology 111(2), 155-164 (2004).
10. Gould DS, Ploegh HL, Schust DJ: Murine female reproductive tract intraepithelial lymphocytes display selection characteristics distinct from both peripheral and other mucosal T cells. J. Reprod. Immunol. 52(1-2), 85-99 (2001).
11. Poles MA, Barsoum S, Yu W et al.: Human immunodefciency virus type 1 induces persistent changes in mucosal and blood gd T cells despite suppressive therapy. J. Virol. 77(19), 10456-10467 (2003).
12. MacDougall A, Enders P, Hatfeld G, Pauza D, Rakasz E: Vg2 TCR repertoire overlap in different anatomical compartments of healthy, unrelated rhesus macaques. J. Immunol. 166(4), 2296-2302 (2001).
13. Rakasz E, MacDougall AV, Zayas MT et al.: gd T cell receptor repertoire in blood and colonic mucosa of rhesus macaques. J. Med. Primatol. 29(6), 387-396 (2000).
14. Cairo C, Armstrong CL, Cummings JS et al.: Impact of age, gender, and race on circulating gd T cells. Hum. Immunol. 71(10), 968-975 (2010).
15. Hviid L, Akanmori BD, Loizon S et al.: High frequency of circulating gd T cells with dominance of the v(d) 1 subset in a healthy population. Int. Immunol. 12(6), 797-805 (2000).
16. Hayday AC: gd T cells and the lymphoid stress-surveillance response. Immunity 31(2), 184-196 (2009).
17. Bonneville M, O'Brien RL, Born WK: gd T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10(7), 467-478 (2010).
18. Adams EJ, Strop P, Shin S, Chien Y-H, Garcia KC: An autonomous CDR3d is suffcient for recognition of the nonclassical MHC class I molecules T10 and T22 by gd T cells. Nat. Immunol. 9(7), 777-784 (2008).
19. Chien YH, Konigshofer Y: Antigen recognition by gd T cells. Immunol. Rev. 215, 46-58 (2007).
20. Constant P, Davodeau F, Peyrat MA et al.: Stimulation of human gd T cells by nonpeptidic mycobacterial ligands. Science 264(5156), 267-270 (1994).
21. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR: Natural and synthetic non-peptide antigens recognized by human gd T cells. Nature 375(6527), 155-158 (1995).
22. Scotet E, David-Ameline J, Peyrat MA et al.: T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J. Exp. Med. 184(5), 1791-1800 (1996).
23. Steinle A, Li P, Morris DL et al.: Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53(4), 279-287 (2001).
24. Aydintug MK, Roark CL, Chain JL, Born WK, O'Brien RL: Macrophages express multiple ligands for gd TCRs. Mol. Immunol. 45(11), 3253-3263 (2008).
25. Bauer S, Groh V, Wu J et al.: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285(5428), 727-729 (1999).
26. Strauss WM, Quertermous T, Seidman JG: Measuring the human T cell receptor g-chain locus. Science 237(4819), 1217-1219 (1987).
27. Leslie DS, Vincent MS, Spada FM et al.: CD1-mediated g/d T cell maturation of dendritic cells. J. Exp. Med. 196(12), 1575-1584 (2002).
28. Fenoglio D, Poggi A, Catellani S et al.: Vd1 T lymphocytes producing IFN-g and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood 113(26), 6611-6618 (2009).
29. Barcy S, De Rosa SC, Vieira J et al.: gd+ T cells involvement in viral immune control of chronic human herpesvirus 8 infection. J. Immunol. 180(5), 3417-3425 (2008).
30. Harris LD, Klatt NR, Vinton C et al.: Mechanisms underlying gd T cell subset perturbations in SIV-infected Asian rhesus macaques. Blood (2010) (Epub ahead of print).
31. Lamb LS Jr, Musk P, Ye Z et al.: Human gd(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant. 27(6), 601-606 (2001).
32. Meeh PF, King M, O'Brien RL et al.: Characterization of the gd T cell response to acute leukemia. Cancer Immunol. Immunother. 55(9), 1072-1080 (2006).
33. + T cells, and their cytocidal potential correlates with viral load. J. Virol. 77(3), 1848-1855 (2003).
34. + gd T cells in the peripheral blood and bone marrow as a selective feature of HIV-1 but not other virus infections. Br. J. Haematol. 100(4), 728-734 (1998).
35. Wesch D, Hinz T, Kabelitz D: Analysis of the TCR Vg repertoire in healthy donors and HIV-1-infected individuals. Int. Immunol. 10(8), 1067-1075 (1998).
36. Poccia F, Boullier S, Lecoeur H et al.: Peripheral Vg9/Vd2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J. Immunol. 157(1), 449-461 (1996).
37. Wallace M, Scharko AM, Pauza CD et al.: Functional gd T-lymphocyte defect associated with human immunodefciency virus infections. Mol. Med. 3(1), 60-71 (1997).
38. Enders PJ, Yin C, Martini F et al.: HIV-mediated gd T cell depletion is specifc for Vg2+ cells expressing the Jg 1.2 segment. AIDS Res. Hum. Retroviruses 19(1), 21-29 (2003).
39. Bordon J, Evans PS, Propp N, Davis CE Jr, Redfeld RR, Pauza CD: Association between longer duration of HIV-suppressive therapy and partial recovery of the Vg2 T cell receptor repertoire. J. Infect. Dis. 189(8), 1482-1486 (2004).
40. Li H, Peng H, Ma P et al.: Association between Vg2Vd2 T cells and disease progression after infection with closely related strains of HIV in China. Clin. Infect. Dis. 46(9), 1466-1472 (2008).
41. Sireci G, Champagne E, Fournie JJ, Dieli F, Salerno A: Patterns of phosphoantigen stimulation of human Vg9/Vd2 T cell clones include Th0 cytokines. Hum. Immunol. 58(2), 70-82 (1997).
42. Evans PS, Enders PJ, Yin C, Ruckwardt TJ, Malkovsky M, Pauza CD: In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vg2-Jg 1.2/Vd2 T-cell receptors. Immunology 104(1), 19-27 (2001).
43. Parker CM, Groh V, Band H et al.: Evidence for extrathymic changes in the T cell receptor g/d repertoire. J. Exp. Med. 171(5), 1597-1612 (1990).
44. +T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens. Cancer Immunol. Immunother. 56(6), 819-829 (2007).
45. Cummings JS, Cairo C, Armstrong C, Davis CE, Pauza CD: Impacts of HIV infection on Vg2Vd2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS. J. Leukoc. Biol. 84(2), 371-379 (2008).
46. Martini F, Urso R, Gioia C et al.: gd T-cell anergy in human immunodefciency virus-infected persons with opportunistic infections and recovery after highly active antiretroviral therapy. Immunology 100(4), 481-486 (2000).
47. Poccia F, Gougeon ML, Agrati C et al.: Innate T-cell immunity in HIV infection: the role of Vg9Vd2 T lymphocytes. Curr. Mol. Med. 2(8), 769-781 (2002).
48. Hebbeler AM, Propp N, Cairo C et al.: Failure to restore the Vg2-Jg 1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin. Immunol. 128(3), 349-357 (2008).
49. Tikhonov I, Deetz CO, Paca R et al.: Human Vg2Vd2 T cells contain cytoplasmic RANTES. Int. Immunol. 18(8), 1243-1251 (2006).
50. + gd T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis. Clin. Immunol. 128(2), 219-227 (2008).
51. Gertner-Dardenne J, Bonnafous C, Bezombes C et al.: Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 113(20), 4875-4884 (2009).
52. Wallace M, Malkovsky M, Carding SR: g/d T lymphocytes in viral infections. J. Leukoc. Biol. 58(3), 277-283 (1995).
53. Maniar A, Zhang X, Lin W et al.: Human gd T lymphocytes induce robust NK cell mediated antitumor cytotoxicity through CD137 engagement. Blood 116(10), 1726-1733 (2010).
54. + T cells confers resistance to suppression by virus-induced regulatory T cells. J. Immunol. 180(8), 5267-5274 (2008).
55. Conti L, Casetti R, Cardone M et al.: Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gd T cells: role of CD86 and infammatory cytokines. J. Immunol. 174(1), 252-260 (2005).
56. Martino A, Casetti R, D'Alessandri A, Sacchi A, Poccia F: Complementary function of gd T-lymphocytes and dendritic cells in the response to isopentenyl- pyrophosphate and lipopolysaccharide antigens. J. Clin. Immunol. 25(3), 230-237 (2005).
57. Della Chiesa M, Romagnani C, Thiel A, Moretta L, Moretta A: Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Blood 108(12), 3851-3858 (2006).
58. Sciammas R, Bluestone JA: TCRgd cells and viruses. Microbes Infect. 1(3), 203-212 (1999).
59. Kaufmann SH, Schaible UE: Antigen presentation and recognition in bacterial infections. Curr. Opin. Immunol. 17(1), 79-87 (2005).
60. Hansen DS, D'Ombrain MC, Schofeld L: The role of leukocytes bearing natural killer complex receptors and killer immunoglobulin-like receptors in the immunology of malaria. Curr. Opin. Immunol. 19(4), 416-423 (2007).
61. Dieli F, Troye-Blomberg M, Farouk SE, Sireci G, Salerno A: Biology of gd T cells in tuberculosis and malaria. Curr. Mol. Med. 1(4), 437-446 (2001).
62. Poquet Y, Kroca M, Halary F et al.: Expansion of Vg9 Vd2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. Infect. Immun. 66(5), 2107-2114 (1998).
63. Sajadi MM, Constantine NT, Mann DL et al.: Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J. Acquir. Immune Defc. Syndr. 50(4), 403-408 (2009).
64. Migueles SA, Connors M: Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 304(2), 194-201 (2010).
65. Riedel DJ, Sajadi MM, Armstrong CL et al.: Natural viral suppressors of HIV-1 have a unique capacity to maintain gd T cells. AIDS 23(15), 1955-1964 (2009).
66. Lane HC: The generation of CD4 T lymphocytes in patients with HIV infection. J. Biol. Regul. Homeost. Agents 9(3), 107-109 (1995).
67. Pereyra F, Addo MM, Kaufmann DE et al.: Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197(4), 563-571 (2008).
68. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogen- containing bisphosphonates inhibit the mevalonate pathway and prevent post- translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13(4), 581-589 (1998).
69. Rogers MJ, Watts DJ, Russell RG: Overview of bisphosphonates. Cancer 80(8 Suppl.), 1652-1660 (1997).
70. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K: Peripheral blood monocytes are responsible for gd T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br. J. Haematol. 144(2), 245-250 (2009).
71. Das H, Wang L, Kamath A, Bukowski JF: Vg2Vd2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98(5), 1616-1618 (2001).
72. Caccamo N, Dieli F, Meraviglia S, Guggino G, Salerno A: gd T cell modulation in anticancer treatment. Curr. Cancer Drug Targets 10(1), 27-36 (2010).
73. Caccamo N, Meraviglia S, Cicero G et al.: Aminobisphosphonates as new weapons for gd T cell-based immunotherapy of cancer. Curr. Med. Chem. 15(12), 1147-1153 (2008).
74. Dieli F, Caccamo N, Meraviglia S: Advances in immunotherapy of castration- resistant prostate cancer: bisphosphonates, phosphoantigens and more. Curr. Opin. Investig. Drugs 9(10), 1089-1094 (2008).
75. Rey J, Veuillen C, Vey N, Bouabdallah R, Olive D: Natural killer and gd T cells in haematological malignancies: enhancing the immune effectors. Trends Mol. Med. 15(6), 275-284 (2009).
76. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR: Human gd T cells: a nonredundant system in the immune- surveillance against cancer. Trends Immunol. 23(1), 14-18 (2002).
77. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M: Stimulation of gd T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2), 384-392 (2000).
78. Wilhelm M, Kunzmann V, Eckstein S et al.: gd T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1), 200-206 (2003).
79. Dieli F, Vermijlen D, Fulfaro F et al.: Targeting human gd T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67(15), 7450-7457 (2007).
80. Huang J, Meixner L, Fernandez S, McCutchan JA: A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 23 (1), 51-57 (2009).
81. Poccia F, Gioia C, Martini F et al.: Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vg9Vd2 T cells. AIDS 23 (5), 555-565 (2009).
82. Colon-Emeric CS, Mesenbrink P, Lyles KW et al.: Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J. Bone Miner. Res. 25(1), 91-97 (2010).
83. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M: Immune reconstitution infammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-ana lysis. Lancet Infect. Dis. 10(4), 251-261 (2010).
84. Li H, Pauza CD: Rapamycin increases the yield and effector function of human gd T cells stimulated in vitro. Cancer Immunol. Immunother. (2010) (Epub ahead of print).
85. Broder S: Twenty-fve years of translational medicine in antiretroviral therapy: promises to keep. Sci. Transl. Med. 2(39), 39ps33 (2010).
86. Maggi E, Mazzetti M, Ravina A et al.: Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 265(5169), 244-248 (1994).